Oxidative stress (OS) plays a central role in the pathogenesis of several cutaneous disorders, including inflammatory dermatoses, photoaging, and carcinogenesis. The imbalance between reactive oxygen species (ROS) production and endogenous antioxidant defenses contributes to inflammation, cellular senescence, and barrier dysfunction. Phytochemicals with antioxidant and anti-inflammatory properties have therefore gained attention as potential therapeutic agents in dermatology. Calendula officinalis (CO) and Matricaria chamomilla (MC) contain bioactive compounds, including carotenoids, flavonoids, terpenoids, and phenolic acids, that modulate redox homeostasis and inflammatory pathways. Evidence from preclinical and clinical studies indicates that CO and MC exert photoprotective effects by reducing UV-induced ROS generation and preserving dermal collagen. Both extracts promote wound healing through fibroblast stimulation, collagen deposition, and antimicrobial activity. In chronic inflammatory dermatoses, including atopic dermatitis (AD) and psoriasis (Pso), CO and MC downregulate pro-inflammatory cytokines, thereby restoring immune balance. Emerging delivery systems have enhanced their skin bioavailability and clinical effectiveness. Collectively, current data support the antioxidant, anti-inflammatory, and regenerative properties of CO and MC, underscoring their potential in maintaining skin homeostasis and protecting against oxidative damage. Further standardized, large-scale clinical studies are warranted to validate their efficacy, safety, and optimal formulations for dermatological use.
Gammeri et al. (Mon,) studied this question.